Biology Reference
In-Depth Information
5. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer.
Nat Rev Cancer
2002;
:331-41.
6. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways
in human pancreatic cancers revealed by global genomic analyses.
Science
2008;
2
:1801-6.
7. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade
for the treatment of cancer.
Oncogene
2007;
321
:3291-310.
8. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in
lung cancer.
Nat Rev Cancer
2007;
26
:169-81.
9. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a
selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Nat Med
1996;
7
:561-6.
10. Cox AD, Der CJ. Ras
2
family signaling:
therapeutic targeting.
Cancer Biol Ther
:599-606.
11. Fritz G. Targeting the mevalonate pathway for improved anticancer therapy.
Curr Cancer
Drug Targets
2009;
2002;
1
:626-38.
12. Frebourg T, Friend SH. Cancer risks from germline p53 mutations.
J Clin Invest
1992;
9
:1637-41.
13. Lavin MF, Shiloh Y. The genetic defect
90
in ataxia-telangiectasia.
Annu Rev Immunol
:177-202.
14. Lehmann AR. DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome
and trichothiodystrophy.
Biochimie
2003;
1997;
15
:1101-11.
15. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. A splicing mutation
affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel
syndrome.
Nat Genet
2003;
85
:497-501.
16. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity.
Nat Rev Cancer
2003;
33
:155-68.
17. Taylor AM, Groom A, Byrd PJ. Ataxia-telangiectasia-like disorder (ATLD)-its clinical presen-
tation and molecular basis.
DNA Repair (Amst)
2004;
3
:1219-25.
18. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a
candidate anti-cancer barrier in early human tumorigenesis.
Nature
2005;
3
:864-70.
19. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility.
Onco-
gene
2006;
434
:5912-9.
20. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse
populations.
Nat Rev Cancer
2007;
25
:937-48.
21. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective.
Nature
2000;
7
:433-9.
22. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer.
Cancer Cell
2003;
408
:421-9.
23. Harper JW, Elledge SJ. The DNA damage response: ten years after.
Mol Cell
2007;
3
:739-45.
24. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage:
Chk1, Chk2, and MK2.
Curr Opin Cell Biol
2009;
28
:245-55.
25. Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AE, Yaffe MB. MAPKAP kinase-2 is a cell
cycle checkpoint kinase that regulates the G2/M transition and S phase progression in
response to UV irradiation.
Mol Cell
2005;
21
:37-48.
26. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-
mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA
damage.
Cancer Cell
2007;
17
:175-89.
27. Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt MA, Wang X, et al. DNA
damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled
by MK2-mediated RNA stabilization.
Mol Cell
2010;
11
:34-49.
40
